Kailyn Lee Kim, MD
Internal Medicine · Stanford
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kim’s office at (650) 723-4000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A187181 · Current
Licensed to practise in California · since 2023 · expires 2027-08-31 · Sidney Kimmel Medical College at Thomas Jefferson University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Internal Medicine
Original Medicare doctor bills
$24,319
Medicare paid this office $24,319 for 156 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 140 | $20,649 | $143 |
| Critical care, first 30-74 minutes | 16 | $3,082 | $171 |
Who their Medicare patients are
156 Original Medicare patients in 2024. Average age 78 · Under 65 9% · 85 and older 29% · Women 47% · Also on Medicaid 42% · Health risk score 3.04. Sicker patients than 9 in 10 peers; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Coronary heart disease 53% · Diabetes 50% · Heart failure 45% · Atrial fibrillation 40% · Depression 35% · COPD 30% · Dementia 30% · Cancer 24% · Stroke 24%.
The office billed $146,245, Medicare allowed $32,363 and paid $24,319; for 167 services of 5 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 156 | 167 | 78 | 3.04 | $146,245 | $24,319 |
| 2023 | 120 | 129 | 77 | 2.39 | $104,838 | $19,945 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 114 | $18,579 | $154 |
Medicaid work
$3,731 in 2024
Medicaid paid $3,731 for 67 billed services this clinician did in 2024, up to 25 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| 1ST HOSP IP/OBS HIGH 75 | 67 | $3,731 |
| 2024 | 67 | 1 | 25 | $3,731 |
| 2023 | 24 | 1 | 12 | $1,006 |
See the largest Medicaid services in earlier years
2023
| 1ST HOSP IP/OBS HIGH 75 | 24 | $1,006 |
Drugs they prescribed that Part D paid
$88,905
Pharmacies billed $88,905 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
40 generic and fewer than 11 brand-name prescriptions · $88,905 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
Year by year
| 2024 | 48 | 21 | None | None | $88,905 |
| 2023 | 255 | 36 | 0% (0) | None | $54,785 |
| 2022 | 363 | 55 | 0% (0) | 17% | $55,213 |
| 2021 | 69 | 23 | 0% (0) | None | $7,721 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Diclofenac | 21 | $484 | $23 |
| Atorvastatin | 19 | $218 | $11 |
| Losartan | 12 | $163 | $14 |
| Metformin | 13 | $150 | $12 |
| Amlodipine Besylate | 11 | $121 | $11 |
2022: 5 drugs
| Diclofenac | 19 | $293 | $15 |
| Atorvastatin | 27 | $256 | $9 |
| Gabapentin | 15 | $230 | $15 |
| Metformin | 21 | $226 | $11 |
| Fluticasone Propionate | 16 | $185 | $12 |
Money from drug and device companies
$1,571 in 2025
| 2025 | 27 | 52 | None | $1,571 |
| 2024 | 13 | 16 | None | $440 |
| 2023 | 2 | 2 | None | $238 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Erleada | $241 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Opdualag | $154 | 9 payments
|
| Genentech USA | Polivy | $113 | 4 payments
|
| Servier Pharmaceuticals | Tibsovo | $108 | 2 payments
|
| Lilly USA | Verzenio | $93 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $77 | 3 payments
|
See all 52 published payments
| Genentech USA | Meals · 2025-12-19 | Tecentriq | $23 |
| Gilead Sciences | Meals · 2025-12-18 | Trodelvy | $31 |
| Genentech USA | Meals · 2025-12-11 | Polivy | $31 |
| Servier Pharmaceuticals | Meals · 2025-12-06 | Tibsovo | $91 |
| Array Biopharma | Meals · 2025-12-04 | Lorbrena | $28 |
| Adc Therapeutics America | Meals · 2025-11-21 | Zynlonta | $33 |
| Agios Pharmaceuticals | Meals · 2025-11-18 | Pyrukynd | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-06 | Lynparza | $29 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-04 | Opdivo | $20 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-04 | Opdivo | $3 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-23 | Opdualag | $26 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-09 | None | $12 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-09 | None | $2 |
| Janssen Biotech | Meals · 2025-10-02 | Erleada | $39 |
| Jazz Pharmaceuticals | Meals · 2025-09-19 | Zepzelca | $33 |
| Agios Pharmaceuticals | Meals · 2025-09-18 | Pyrukynd | $23 |
| Coherus Oncology | Meals · 2025-09-16 | Loqtorzi | $27 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-11 | None | $8 |
| Abbvie | Meals · 2025-09-05 | Elahere | $25 |
| Alexion Pharmaceuticals | Meals · 2025-09-04 | Ultomiris | $42 |
| Janssen Biotech | Meals · 2025-09-02 | Erleada | $32 |
| Menarini Silicon Biosystems | Meals · 2025-08-26 | Cellsearch | $32 |
| Deciphera Pharmaceuticals | Meals · 2025-08-19 | Qinlock | $29 |
| Genentech USA | Meals · 2025-08-15 | Polivy | $32 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-07 | Opdualag | $28 |
| Incyte | Meals · 2025-08-05 | Jakafi | $29 |
| Incyte | Meals · 2025-07-29 | Monjuvi | $24 |
| BeOne Medicines USA | Meals · 2025-07-24 | Tevimbra | $33 |
| Menarini Silicon Biosystems | Meals · 2025-07-22 | Cellsearch | $21 |
| Celgene | Meals · 2025-07-18 | Reblozyl | $18 |
| Daiichi Sankyo | Meals · 2025-07-17 | Datroway | $29 |
| Kyowa Kirin | Meals · 2025-07-17 | Poteligeo | $21 |
| Janssen Biotech | Meals · 2025-07-15 | Erleada | $40 |
| Servier Pharmaceuticals | Meals · 2025-07-09 | Tibsovo | $18 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-30 | Opdivo | $25 |
| Karyopharm Therapeutics | Meals · 2025-05-29 | Xpovio | $29 |
| Janssen Biotech | Meals · 2025-05-22 | Erleada | $30 |
| Janssen Biotech | Education · 2025-05-21 | Rybrevant | $100 |
| Lilly USA | Education · 2025-05-14 | None | $61 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-08 | Lynparza | $27 |
| Lilly USA | Meals · 2025-05-02 | Verzenio | $32 |
| Seagen | Education · 2025-04-24 | None | $75 |
| Pfizer | Meals · 2025-04-24 | Ibrance | $32 |
| Exelixis | Meals · 2025-04-10 | Cabometyx | $41 |
| Genentech USA | Meals · 2025-04-04 | Tecentriq | $26 |
| Blueprint Medicines | Meals · 2025-04-03 | Ayvakit | $36 |
| Celgene | Meals · 2025-04-02 | Reblozyl | $16 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-28 | Tagrisso | $21 |
| Celgene | Meals · 2025-03-07 | Reblozyl | $16 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-06 | Opdualag | $29 |
| Celgene | Meals · 2025-01-17 | Reblozyl | $18 |
| Geron | Meals · 2025-01-16 | Rytelo | $24 |
See earlier years (2024, 2023)
2024: $440
| Celgene | Reblozyl | $89 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $51 | 2 payments
|
| Agios Pharmaceuticals | None | $39 | 1 payment
|
| Janssen Biotech | Darzalex | $32 | 1 payment
|
| Ipsen Biopharmaceuticals | Onivyde | $32 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $30 | 1 payment
|
| BeiGene USA | Brukinsa | $29 | 1 payment
|
| Exelixis | Cabometyx | $28 | 1 payment
|
| X4 Pharmaceuticals | Xolremdi | $28 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $23 | 1 payment
|
| Genentech USA | Tecentriq | $21 | 1 payment
|
| Aveo Pharmaceuticals | Fotivda | $20 | 1 payment
|
| Abbvie | Elahere | $18 | 1 payment
|
2023: $238
| Melinta Therapeutics | Vabomere | $130 | 1 payment
|
| Astellas Pharma US | Cresemba | $108 | 1 payment
|
Professional record
- NPI
- 1518595768
- Licence
- CA A187181California A187181: Current · expires 2027-08-31
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2020-03-31
- NPI last updated
- 2024-04-19
- NPI record certified
- 2024-04-19
This is when the NPI record was last certified, not a medical board exam.